指南与共识血管炎

欧洲抗风湿病联盟关于抗中性粒细胞胞质抗体相关血管炎管理的推荐:2022年更新版

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
指南 / 共识 · Ann Rheum Dis · 2024-01-02

该2022年更新版基于EULAR标准化操作流程,由来自16个国家的20位专家通过系统文献回顾形成4条总体原则和17条推荐。推荐内容包括:活检和ANCA检测辅助诊断;危及生命或器官的AAV诱导缓解采用大剂量糖皮质激素联合利妥昔单抗或环磷酰胺;糖皮质激素在4-5个月内逐渐减至泼尼松龙等效5 mg/天的目标;GPA或MPA可考虑阿伐可泮以减少糖皮质激素暴露;快速进展性肾小球肾炎可考虑血浆置换;GPA/MPA维持缓解推荐利妥昔单抗;复发或难治性EGPA推荐美泊利单抗;硫唑嘌呤和甲氨蝶呤是生物制剂的替代选择。

要点

  • 推荐活检和ANCA检测辅助AAV诊断。
  • 危及生命或器官的AAV诱导缓解:大剂量糖皮质激素联合利妥昔单抗或环磷酰胺。
  • GPA/MPA维持缓解推荐利妥昔单抗;硫唑嘌呤和甲氨蝶呤为替代选择。

核心结论

  • 这些推荐基于近期进展,为AAV管理提供更新指导;因仍存在大量数据空白,医生与患者之间的知情决策仍至关重要。

研究设计与样本

  • EULAR工作组采用EULAR标准化操作流程,进行系统文献回顾并征求来自16个国家的20位专家意见,修改现有推荐并制定新推荐。

主要发现

  • 共制定4条总体原则和17条推荐。

关键数值与推荐

  • 推荐活检和ANCA检测以辅助确立AAV诊断。
  • 对于危及生命或危及器官的AAV诱导缓解,推荐大剂量糖皮质激素联合利妥昔单抗或环磷酰胺。
  • 推荐糖皮质激素剂量在4-5个月内逐渐减至泼尼松龙等效5 mg/天的目标。
  • 在肉芽肿性多血管炎(GPA)或显微镜下多血管炎(MPA)中,可考虑将阿伐可泮作为减少糖皮质激素暴露策略的一部分。
  • 对于快速进展性肾小球肾炎患者,可考虑血浆置换。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出仍存在大量数据空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. METHODS: Using EULAR standardised operating procedures, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 16 countries. We modified existing recommendations and created new recommendations. RESULTS: Four overarching principles and 17 recommendations were formulated. We recommend biopsies and ANCA testing to assist in establishing a diagnosis of AAV. For remission induction in life-threatening or organ-threatening AAV, we recommend a combination of high-dose glucocorticoids (GCs) in combination with either rituximab or cyclophosphamide. We recommend tapering of the GC dose to a target of 5 mg prednisolone equivalent/day within 4-5 months. Avacopan may be considered as part of a strategy to reduce exposure to GC in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Plasma exchange may be considered in patients with rapidly progressive glomerulonephritis. For remission maintenance of GPA/MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab. Azathioprine and methotrexate are alternatives to biologics for remission maintenance in AAV. CONCLUSIONS: In the light of recent advancements, these recommendations provide updated guidance on AAV management. As substantial data gaps still exist, informed decision-making between physicians and patients remains of key relevance.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024. PMID: 36927642. doi:10.1136/ard-2022-223764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。